CLINICAL_TRIALS
trial_result
· 2023-10-30
Clinical Trial Update: An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer [Phase 2]
Summary
Open-label Phase 2 trial results for encorafenib plus binimetinib in BRAFV600-mutant non-small cell lung cancer have been completed and posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-10-30